SCD represents a distinct clinical phase characterized by patient‐reported cognitive concerns, with tau‐PET positivity typically emerges in the medial temporal lobe,288 paralleled by increased t‐tau concentrations in tears. Here, MAPT is linked to Schnyder corneal dystrophy.